ASNR 2012 Methodology for Imaging Genomics of Gliomas

Slides:



Advertisements
Similar presentations
John A. Barrett Ph.D. Ziopharm Oncology, Boston MA 02129
Advertisements

Tianyu Zhan, Sharon Huang, Nallammai Muthiah, Evangeline Giannopoulos, J Peter Gergen Stony Brook University, Department of Biochemistry and Cell Biology.
A phase I dose escalating study of intensity modulated radiation therapy (IMRT) for the treatment of glioblastoma multiforme (GBM) ( #1008) V. Stieber.
Transforming Correlative Science to Predictive Personalized Medicine Richard Simon, D.Sc. National Cancer Institute
 2013 Genentech USA, Inc. All rights reserved. Disclosure/Disclaimer The Molecular Biomarkers in Cancer (MBiC) slide presentation is not an independent.
16 November 2004Biomedical Imaging BMEN Biomedical Imaging of the Future Alvin T. Yeh Department of Biomedical Engineering Texas A&M University.
Ginu A. Thomas, MD; Ahmed Elakkad, MD; Mohamed Elbanan, MD;
Functional Diffusion Maps (fDMs) for Brain Tumor Treatment Response Monitoring Benjamin M. Ellingson, Ph.D. Assistant Professor of Radiology Dept. of Radiological.
Introduction Integrative Analysis of Genomic Variants in Carcinogenesis Syed Haider, Arek Kasprzyk, Pietro Lio Artificial Intelligence and Computational.
Inferior Brain Lesions Monitored Using Diffusion Weighted Magnetic Resonance Imaging Lars Ewell 1, Naren Vijayakumar 2, Jeffrey J. Rodriguez 2 and Baldassarre.
McDaniels – Feb 29, Outline Patient 6 question Patient 11 ADC results Abstract for AAPM conference.
Genomic signatures to guide the use of chemotherapeutics Authors: Anil Potti et. al Presenter: Jong Cheol Jeong.
RADIOLOGY Technology Trends and Their Impact on American Healthcare Monte Clinton, CRA Director of Radiology Dartmouth-Hitchcock Medical Center Lebanon,
NA-MIC National Alliance for Medical Image Computing Non-rigid MR-CT Image Registration Atsushi Yamada, Dominik S. Meier and Nobuhiko.
Clinical Trials, TCGA: Deep Integrative Research RT, Imaging, Pathology, “omics” Joel Saltz MD, PhD Director Center for Comprehensive Informatics.
CaGrid, Fog and Clouds Joel Saltz MD, PhD Director Center for Comprehensive Informatics.
ACRIN Abdominal Committee ACRIN Gynecologic Committee Fall Meeting 2010.
Epidemiological study on INVASIVE BREAST CANCER treated at Hotel Dieu de France Hospital University of Saint-Joseph Faculty of Medicine Gerard Abadjian,
Shutter-Speed Model DCE-MRI for Assessment of Response to Cancer Therapy U01 CA154602; Wei Huang, PhD, Christopher Ryan, MD; Oregon Health & Science University,
Imaging Genomics: Correlation of Invasive Genomic Composition and Patient Survival Using Qualitative and Quantitative MR Imaging Parameters RR Colen 1,
© NIH National Center for Image-Guided Therapy, 2011 Tumor Segmentation from DCE-MRI with the SegmentCAD module Vivek Narayan, Jayender Jagadeesan Brigham.
Idoia Corcuera-Solano, Gerard Reddy, Bradley Delman, Reade De Leacy, Dan Rettmann, Lawrence N Tanenbaum EP
Radiogenomics in glioblastoma multiforme
THE CORRELATIONS OF 3D PSEUDO-CONTINUOUS ARTERIAL SPIN LABELING AND DYNAMIC SUSCEPTIBILITY CONTRAST PERFUSION MRI IN BRAIN TUMORS Delgerdalai Khashbat,
QUANTITATIVE MRI OF GLIOBLASTOMA RESPONSE Bruce Rosen, MD, PhD Athinoula A. Martinos Center for Biomedical Imaging, MGH. Future Plans/Upcoming Trials Reproducibility.
Summit on Drug Discovery Tuberous Sclerosis Alliance July 7, 2011 Biomarkers in TSC and LAM.
Department of Radiology and Imaging Sciences Division of Neuroradiology University School of Medicine.
ASNR 2015 Poster# EP-19 Effect of Chemotherapy on Brain Structure and Cognition in Older Women with Breast Cancer: a Brain MRI Study 1 Bihong T. Chen MD.
Prediction of Glioblastoma Multiforme Patient Time to Recurrence Using MR Image Features and Gene Expression Nicolasjilwan, M.1·Clifford, R.2·Flanders,
© NlH National Center for Image Guided Therapy, 2012 ASNR 2012 Imaging Genomic mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme.
Author Name 2, Author Name 5 1 Dept. of Neurology, 2 Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA To demonstrate.
Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,
Genomic mapping and survival prediction in GBM: Molecular sub-classification as an adjunct to hemodynamic imaging biomarkers - A TCGA Glioma Phenotype.
Jalal Jalal Shokouhi-MD General secretary of Iranian society of Radiology
Using Predictive Classifiers in the Design of Phase III Clinical Trials Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute.
Diffusion Physics H 2 O in the body is always in random motion due to thermal agitation B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen.
Diffusion tensor imaging reveals early dissemination of pediatric diffuse intrinsic pontine gliomas Matthias W. Wagner¹, Joyce Mhlanga¹, Thangamadhan Bosemani¹,
Exploring Peritumoral White Matter Fibers for Neurosurgical Planning Sonia Pujol, Ph.D. Ron Kikinis, M.D. Surgical Planning Laboratory Harvard University.
Prediction of Glioblastoma Multiforme Patient Survival Using MR Image Features and Gene Expression Control/Tracking Number: 11-O-1519-ASNR Nicolasjilwan,
Correlation of Leptomeningeal Disease on MRI Between the Brain and Spine in Patients Presenting to a Tertiary Referral Center Poster #: EP-47 Control #:
ICNCT-16, June 2014, Helsinki Glioma heterogeneity and the L-Amino acid transporter-1 (LAT1): A first step to stratified BPA-based BNCT? D. Ngoga 1 ; C.
Introduction to caIntegrator caBIG ® Molecular Analysis Tools Knowledge Center April 3, 2011.
©2005 Surgical Planning Laboratory, ARR Slide 1 Prostate Image Processing Steven Haker, PhD.
Presented By Christina Tsien at 2014 ASCO Annual Meeting.
Jin MENG Shen FU (DPD 08) Biology 2 - Head/Neck and CNS Tumors
Learning disjunctions in Geronimo’s regression trees Felix Sanchez Garcia supervised by Prof. Dana Pe’er.
Purpose N-isopropylacrylamide (NIPAM) polymer gel dosimeters were employed to verify the dose distribution of clinical intensity modulated radiation therapy.
Molecular Biomarkers & Targets an overview Michael Messenger NIHR Diagnostic Evidence Co-Operative & Leeds Cancer Research UK Centre.
S. CONDETTE-AULIAC 1, A. BOULIN 1, O. COSKUN 1, L. BOZEC-LE MOAL 2, S. ALDEA 3, S.GUIEU 1, G. RODESCH 1. 1 Neuroradiology department, 2 Oncology department,
ASNR 54rd Annual Meeting ASNR 54rd Annual Meeting
J Cho, G Ibbott, M Kerr, R Amos, and O Mawlawi
miRNA-targets cross-talks: key players in glioblastoma multiforme
Molecularly targeted therapy and radiogenomic imaging in glioblastoma
Proton range verification with PET: 68Zn, Cu and polycarbonate activation SNMMI Young Investigator Symposium, Vancouver, June 9, 2013 Cho J1, Ibbott.
Feasibility of hippocampal sparing radiation therapy for glioblastoma using helical Tomotherapy Dr Kamalram THIPPU JAYAPRAKASH1,2,3, Dr Raj JENA1,4 and.
MR images analysis of glioma
Ron Kikinis, MD Professor of Radiology, Harvard Medical School
Non-rigid MR-CT Image Registration
Figure 1. A: T1-weighted MRI shows enhanced lesion with peripheral edema on left frontal area, compatible with high grade glioma. B: Left frontal area.
CT-based surrogates of pulmonary ventilation in lung cancer:
Fig year-old female patient with two months of headaches and falls and a remote history of right lung lobectomy for reported benign tumor with MR.
2SAIC-Frederick, Inc. 3Boston University School of Medicine
Loyola Marymount University
Eric H. Raabe, Charles G. Eberhart  Cancer Cell 
Tumor Segmentation from DCE-MRI with OpenCAD
Molecular prognostication of liver cancer: End of the beginning
Loyola Marymount University
Loyola Marymount University
Loyola Marymount University
Presentation transcript:

ASNR 2012 Methodology for Imaging Genomics of Gliomas Rivka R. Colen, M.D.1, Bhanu Mahajan, M.B.B.S.1, Arpad Kovacs, M.D.1, Pascal O. Zinn, M.D.2, Ferenc A. Jolesz, M.D.1 1 Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA. 2 M.D. Anderson Cancer Center, Houston, TX, USA. © NlH National Center for Image Guided Therapy, 2012

© NlH National Center for Image Guided Therapy, 2012 Disclosures No Disclosures. R25 CA089017(RRC) P41 RR019703 (FAJ) © NlH National Center for Image Guided Therapy, 2012

© NlH National Center for Image Guided Therapy, 2012 Imaging Genomics Imaging Genomics has emerged as a new field which links gene expression profiles with MRI phenotypes. MRI (radio) phenotypes( necrosis, edema/tumor infiltration, contrast enhancement, perfusion, diffusion) correlated with underlying genomic composition (genes, microRNAs, etc) © NlH National Center for Image Guided Therapy, 2012

© NlH National Center for Image Guided Therapy, 2012 Imaging Genomics Quantitative image analysis results in more precise and reproducible results and can then be correlated with genomics. In imaging genomics, tumor volumetrics has the potential to uncover genomic targets for subsequent development into cancer therapeutics. This was first described by Zinn et al in 2011 where an invasive gene and microRNA was uncovered using the FLAIR volume as an MRI biomarker (radiophenotype). Zinn PO, Majadan B, Sathyan P, Singh SK, Majumder S, Jolesz FA, Colen RR. Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme. PLoS One. 2011;6(10):e25451 © NlH National Center for Image Guided Therapy, 2012

© NlH National Center for Image Guided Therapy, 2012 Purpose In this study, we seek demonstrate the methodology for imaging genomic brain tumor volumetric analysis and its feasibility. © NlH National Center for Image Guided Therapy, 2012

© NlH National Center for Image Guided Therapy, 2012 Imaging Genomics Here, we demonstrate the methodology and feasibility for the first comprehensive radiogenomic analysis using quantitative MRI volumetrics and large-scale gene- and microRNA expression profiling in Glioblastoma Multiforme (GBM). © NlH National Center for Image Guided Therapy, 2012

© NlH National Center for Image Guided Therapy, 2012 Methods and Materials Retrospective study of 78 treatment naïve GBM patients Image data used in this research were obtained from The Cancer Imaging Archive (http://cancerimagingarchive.net/) sponsored by the Cancer Imaging Program, DCTD/NCI/NIH. Imaging was correlated with Gene- and micoRNA- expression profiles obtained from The Cancer Genome Atlas (TCGA) http://cancergenome.nih.gov © NlH National Center for Image Guided Therapy, 2012

© NlH National Center for Image Guided Therapy, 2012 Methods and Materials T2/FLAIR was rigidly aligned and registered to the post- contrast T1WI. © NlH National Center for Image Guided Therapy, 2012

Methods and Materials Segmentation Slicer 3.6 (slicer.org) Volumes were obtained using the segmentation module of Slicer © NlH National Center for Image Guided Therapy, 2012

© NlH National Center for Image Guided Therapy, 2012 Methods and Materials Volumetric segmentation was performed in a simple hierarchical model of anatomy, proceeding from peripheral to central. Edema Contrast Enhancement Necrosis Zinn PO, Majadan B, Sathyan P, Singh SK, Majumder S, Jolesz FA, Colen RR. Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme. PLoS One. 2011;6(10):e25451 © NlH National Center for Image Guided Therapy, 2012

© NlH National Center for Image Guided Therapy, 2012 Methods and Materials This results in 3 distinct structures being segmented: Edema/invasion Enhancing tumor Necrosis Tumor Segmentation. 65 year old male patient with a right temporal GBM. Segmentation of tumor edema (blue), enhancement (yellow) and necrosis (red) was performed and edema volume was obtained. © NlH National Center for Image Guided Therapy, 2012

© NlH National Center for Image Guided Therapy, 2012 Methods and Materials Fluid-attenuated inversion recovery (FLAIR) was used for segmentation of the edema Edema © NlH National Center for Image Guided Therapy, 2012

© NlH National Center for Image Guided Therapy, 2012 Methods and Materials Post contrast T1-weighted imaging (T1W1) for segmentation of enhancement(tumor) and necrosis Necrosis Contrast enhancement © NlH National Center for Image Guided Therapy, 2012

© NlH National Center for Image Guided Therapy, 2012 Methods and Materials Slicer Model Making Module for Volume calculations Models (Volumes) of Edema, Tumor and Necrosis were generated from previously performed segmentations. © NlH National Center for Image Guided Therapy, 2012

© NlH National Center for Image Guided Therapy, 2012 Methods and Materials Volumes of each radiophenotype ( edema/tumor infiltration, enhancing tumor, and necrosis) were then correlated with the genomic findings. Zinn PO, Majadan B, Sathyan P, Singh SK, Majumder S, Jolesz FA, Colen RR. Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme. PLoS One. 2011;6(10):e25451 © NlH National Center for Image Guided Therapy, 2012

© NlH National Center for Image Guided Therapy, 2012 Results In most scans, image registration was almost 100% Scans where complex rotational modifications and registration were required, registration was deemed adequate when error was 2mm or less. © NlH National Center for Image Guided Therapy, 2012

© NlH National Center for Image Guided Therapy, 2012 Results Quantitative volumes of edema/invasion, enhancement and necrosis were in high correlation with biologically concordant functional genomic targets. MRI-FLAIR radiophenotype readily and noninvasively detected key cancer genomic components responsible for cellular migration and invasion in GBM. Zinn PO, Majadan B, Sathyan P, Singh SK, Majumder S, Jolesz FA, Colen RR. Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme. PLoS One. 2011;6(10):e25451 © NlH National Center for Image Guided Therapy, 2012

© NlH National Center for Image Guided Therapy, 2012 Conclusion Quantitative imaging genomic analysis is simple. Imaging surrogates/ biomarkers using conventional MRI radiophenotypes of necrosis, enhancing tumor and edema/tumor infiltration reflect specific genomic composition in GBM. Quantitative imaging genomic analysis allow for predictions of key genetic events. Quantitative imaging genomic analysis can screen for novel genomic targets for possible subsequent development of targeted therapeutics. Stratify patients based on their genetic/molecular makeup into responders versus non-responders to a particular treatment. The ability to determine uncover genomic targets from routine clinical MRI examinations and thus subsequently determine if a patient is a candidate for that genomic therapy is a major step towards personalized medicine. © NlH National Center for Image Guided Therapy, 2012

Thank you for your interest! Conclusion Thank you for your interest! Acknowledgements: This work was supported by NIH grant R25 CA089017-06A2 (RRC). Any questions please email: rrcolen@gmail.com. © NlH National Center for Image Guided Therapy, 2012